Latest news with #AccretionPharmaceuticals
Business Standard
21-05-2025
- Business
- Business Standard
NSE SME Accretion Pharma stumbles on market debut
Shares of Accretion Pharmaceuticals was trading at Rs 82.95 on the NSE, a discount of 17.87% compared with the issue price of Rs 101. The scrip was listed at 79, a discount of 21.78% over the initial public offer (IPO) price. The stock was currently frozen at its upper limit of 5% over its listing price. The counter hit a high of Rs 82.95 and a low of Rs 75.05. About 4.48 lakh shares of the company changed hands at the counter. Accretion Pharmaceuticals' IPO was subscribed 7.31 times. The issue opened for bidding on 14 May 2025 and it closed on 16 May 2025. The price band of the IPO was set at Rs 96 to Rs 101 per share. The IPO comprised fresh issue of 29,46,000 equity shares. The promoter and promoter group shareholding diluted to 73.14% from 100% pre-issue. The company intends to utilize the net proceeds for capital expenditure towards the purchase of new equipment and machinery, capital expenditure for the upgradation of the existing manufacturing facility, repayment or prepayment of certain borrowings availed by the company, funding of working capital requirements and for general corporate purposes. Ahead of the Accretion Pharmaceuticals on 13 May 2025, raised Rs 2.13 crore from anchor investors. The company allotted 2.11 lakh shares at Rs 101 per share to 2 anchor investors. Accretion Pharmaceuticals is engaged in the business of manufacturing and marketing tablets, capsules, oral liquids, external preparations (ointments, creams, gels, lotions, medicated shampoos, mouthwash, dusting powder), and oral powders (sachets, dry syrup), etc. Apart from manufacturing products for direct sales, the company also manufactures various pharmaceutical products for different marketers on a loan license or contract manufacturing basis. Its business is primarily carried out on a principal-to-principal basis with different marketers. The company had a total of 105 employees. The company recorded revenue from operations of Rs 35.67 crore and net profit of Rs 5.24 crore for the period ended 31 December 2024.
Economic Times
21-05-2025
- Business
- Economic Times
Accretion Pharmaceuticals IPO listing today. Check GMP ahead of debut
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Accretion Pharmaceuticals, a Gujarat-based pharma manufacturer , concluded its Rs 29.75 crore SME IPO on May 16. The issue, priced between Rs 96 and Rs 101 per share, comprised a fresh issue of 29.46 lakh equity shares. Despite a strong subscription of 7.31 times, the grey market premium (GMP) has remained flat at Rs 0, suggesting a cautious market sentiment ahead of its listing on the NSE SME IPO witnessed robust participation across investor categories: Qualified Institutional Buyers (QIBs) subscribed 12.14 times, retail investors 10.54 times, and Non-Institutional Investors (NIIs) 3.93 Pharmaceuticals, established in 2012, specializes in manufacturing and marketing a diverse range of pharmaceutical products, including tablets, capsules, oral liquids, external preparations, and oral a presence in over 20 countries across Africa, Southeast Asia, and the Middle East, Accretion has established itself as a significant player in the pharmaceutical the company has shown impressive growth. For the fiscal year 2024, Accretion reported a revenue of Rs 33.94 crore, up from Rs 29.53 crore in the previous year, and a profit after tax of Rs 3.88 crore, a substantial increase from Rs 0.10 crore in FY23. These figures indicate a strong upward trajectory in both revenue and proceeds from the IPO are earmarked for capital expenditures, including the purchase of new equipment and machinery, upgrading existing manufacturing facilities, repayment of certain borrowings, funding working capital requirements, and general corporate the strong fundamentals and investor interest, the absence of a grey market premium suggests a cautious approach from the market, possibly due to broader market conditions or sector-specific factors. Investors and market watchers will be keenly observing the stock's performance upon listing to gauge its reception in the public market.
Time of India
21-05-2025
- Business
- Time of India
Accretion Pharmaceuticals IPO listing today. Check GMP ahead of debut
Accretion Pharmaceuticals, a Gujarat-based pharma manufacturer , concluded its Rs 29.75 crore SME IPO on May 16. The issue, priced between Rs 96 and Rs 101 per share, comprised a fresh issue of 29.46 lakh equity shares. Despite a strong subscription of 7.31 times, the grey market premium (GMP) has remained flat at Rs 0, suggesting a cautious market sentiment ahead of its listing on the NSE SME platform. The IPO witnessed robust participation across investor categories: Qualified Institutional Buyers (QIBs) subscribed 12.14 times, retail investors 10.54 times, and Non-Institutional Investors (NIIs) 3.93 times. Accretion Pharmaceuticals, established in 2012, specializes in manufacturing and marketing a diverse range of pharmaceutical products, including tablets, capsules, oral liquids, external preparations, and oral powders. With a presence in over 20 countries across Africa, Southeast Asia, and the Middle East, Accretion has established itself as a significant player in the pharmaceutical sector. Financially, the company has shown impressive growth. For the fiscal year 2024, Accretion reported a revenue of Rs 33.94 crore, up from Rs 29.53 crore in the previous year, and a profit after tax of Rs 3.88 crore, a substantial increase from Rs 0.10 crore in FY23. These figures indicate a strong upward trajectory in both revenue and profitability. Live Events The proceeds from the IPO are earmarked for capital expenditures, including the purchase of new equipment and machinery, upgrading existing manufacturing facilities, repayment of certain borrowings, funding working capital requirements, and general corporate purposes. Despite the strong fundamentals and investor interest, the absence of a grey market premium suggests a cautious approach from the market, possibly due to broader market conditions or sector-specific factors. Investors and market watchers will be keenly observing the stock's performance upon listing to gauge its reception in the public market.
Business Standard
19-05-2025
- Business
- Business Standard
NSE SME Accretion Pharmaceuticals' IPO ends with subscription of 7.31 times
The offer received bids for 2 crore shares as against 27.35 lakh shares on offer. The initial public offer (IPO) of Accretion Pharmaceuticals received bids for 2,00,06,400 shares as against 27,34,800 shares on offer. The issue was subscribed 7.31 times. Retail investors bid for 1,28,95,200 shares, non-institutional investors bid for 53,91,600 shares and qualified institutional investors bid for 17,19,600 shares. The issue opened for bidding on 14 May 2025 and it closed on 16 May 2025. The price band of the IPO was set at Rs 96 to Rs 101 per share. The equity shares will list on NSEs SME platform. The IPO comprised fresh issue of 29,46,000 equity shares. The promoter and promoter group shareholding diluted to 73.14% from 100% pre-issue. The company intends to utilize the net proceeds for capital expenditure towards the purchase of new equipment and machinery, capital expenditure for the upgradation of the existing manufacturing facility, repayment or prepayment of certain borrowings availed by the company, funding of working capital requirements and for general corporate purposes. Ahead of the Accretion Pharmaceuticals on 13 May 2025, raised Rs 2.13 crore from anchor investors. The company allotted 2.11 lakh shares at Rs 101 per share to 2 anchor investors. Accretion Pharmaceuticals is engaged in the business of manufacturing and marketing tablets, capsules, oral liquids, external preparations (ointments, creams, gels, lotions, medicated shampoos, mouthwash, dusting powder), and oral powders (sachets, dry syrup), etc. Apart from manufacturing products for direct sales, the company also manufactures various pharmaceutical products for different marketers on a loan license or contract manufacturing basis. Its business is primarily carried out on a principal-to-principal basis with different marketers. The company had a total of 105 employees. The company recorded revenue from operations of Rs 35.67 crore and net profit of Rs 5.24 crore for the period ended 31 December 2024.
News18
19-05-2025
- Business
- News18
Accretion Pharmaceuticals IPO Allotment Today: A Step-By-Step Guide To Check Status Online, Know Latest GMP
Last Updated: Unlisted shares of Accretion Pharmaceuticals Ltd are currently trading at Rs 101 apiece, which is zero premium (GMP) over the IPO price of Rs 101. Accretion Pharma IPO Allotment Today: The share allotment of the Accretion Pharmaceuticals IPO, which closed on May 16 with a 7.67 times subscription, is scheduled to be finalised today, Monday, May 19. Once finalised, investors will start getting bank debit messages. They can also check the IPO allotment status online on registrar Kfin Technologies Ltd's website as well as on the NSE's portal. The NSE SME IPO, which was open for public subscription between May 14 and May 16, received a 7.67 times subscription garnering bids for 1,98,42,000 shares as against 25,87,200 shares on offer. The retail and NII participation stood at 10.54 times and 4.28 times, respectively. Its qualified institutional buyer (QIB) category got a 12.14 times subscription. The IPO allotment is expected to take place today, May 19, in the evening. Once allotted, investors can check the allotment status by following these steps: Step 3: Enter 'application number/ CAF No.', 'Demat Account', or 'PAN number'. According to market observers, unlisted shares of Accretion Pharmaceuticals Ltd are currently trading at Rs 101 apiece, which is zero premium (GMP) over the IPO price of Rs 101. Its listing is scheduled to take place on May 21 on both the NSE Emerge platform. The GMP is based on market sentiments and keeps changing. 'Grey market premium' indicates investors' readiness to pay more than the issue price. Accretion Pharmaceuticals IPO: More Details The Rs 29.75-crore Accretion Pharmaceuticals IPO is entirely a fresh issue of 29.46 lakh shares. Its price band was fixed at Rs 101 per share. The bidding started on May 14, 2025 and closed on May 16, 2025. The IPO allotment is scheduled to be finalised on Monday, May 19, 2025. Its shares will be list on the NSE SME on Wednesday, May 21, 2025. Accretion Pharmaceuticals Limited, which was set up in 2012, is a pharmaceutical company that manufactures and sells tablets, capsules, and other healthcare products. It also offers contract manufacturing services. The Company manufactures and markets Tablets, Capsules, Oral Liquids, External Preparations (Ointment, Cream, Gel, Lotion, Medicated Shampoo, Mouthwash, Dusting Powder), and Oral Powder (Sachet, Dry Syrup). Jawa Capital Services Private Limited is the book-running lead manager of the Accretion Pharmaceuticals IPO, while Kfin Technologies Limited is the registrar for the market maker for Accretion Pharmaceuticals IPO is Gretex Share Broking Private Limited. First Published: May 19, 2025, 10:29 IST
